<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Exhaled nitric oxide levels to guide treatment for children with asthma - Petsky, HL - 2016 | Cochrane Library</title> <meta content="Exhaled nitric oxide levels to guide treatment for children with asthma - Petsky, HL - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011439.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Exhaled nitric oxide levels to guide treatment for children with asthma - Petsky, HL - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011439.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011439.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Exhaled nitric oxide levels to guide treatment for children with asthma" name="citation_title"/> <meta content="Helen L Petsky" name="citation_author"/> <meta content="Griffith University" name="citation_author_institution"/> <meta content="helenpetsky@gmail.com" name="citation_author_email"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="BMJ" name="citation_author_institution"/> <meta content="Anne B Chang" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD011439.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/11/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011439.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011439.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011439.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Adrenal Cortex Hormones [*administration &amp; dosage]; Anti-Asthmatic Agents [*administration &amp; dosage]; Asthma [*drug therapy]; Breath Tests; Disease Progression; Exhalation; Nitric Oxide [*analysis]; Randomized Controlled Trials as Topic; Spirometry" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011439.pub2&amp;doi=10.1002/14651858.CD011439.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011439\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011439\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","hr","fr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011439.pub2",title:"Exhaled nitric oxide levels to guide treatment for children with asthma",firstPublishedDate:"Nov 8, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011439.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011439.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011439.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011439.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011439.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011439.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011439.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011439.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011439.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011439.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3525 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011439.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0115"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-sec-0109"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/appendices#CD011439-sec-0120"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/table_n/CD011439StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/table_n/CD011439StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Exhaled nitric oxide levels to guide treatment for children with asthma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information#CD011439-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Helen L Petsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information#CD011439-cr-0003">Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information#CD011439-cr-0004">Anne B Chang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information/en#CD011439-sec-0137">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 November 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011439.pub2">https://doi.org/10.1002/14651858.CD011439.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011439-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011439-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011439-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011439-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011439-abs-0001" lang="en"> <section id="CD011439-sec-0001"> <h3 class="title" id="CD011439-sec-0001">Background</h3> <p>Asthma guidelines aim to guide health practitioners to optimise treatment for patients to minimise symptoms, improve or maintain good lung function, and prevent acute exacerbations. The principle of asthma guidelines is based on a step‐up or step‐down regimen of asthma medications to maximise health using minimum doses. Fractional exhaled nitric oxide (FeNO) is a marker of eosinophilic inflammation and tailoring asthma medications in accordance to airway eosinophilic levels may improve asthma outcomes such as indices of control or reduce exacerbations, or both. </p> </section> <section id="CD011439-sec-0002"> <h3 class="title" id="CD011439-sec-0002">Objectives</h3> <p>To evaluate the efficacy of tailoring asthma interventions based on fractional exhaled nitric oxide (FeNO), in comparison to not using FeNO, that is, management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines (or both), for asthma‐related outcomes in children. </p> </section> <section id="CD011439-sec-0003"> <h3 class="title" id="CD011439-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and reference lists of articles. The last searches were in June 2016. </p> </section> <section id="CD011439-sec-0004"> <h3 class="title" id="CD011439-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) comparing adjustment of asthma medications based on FeNO levels compared to those not using FeNO, that is, management based on clinical symptoms or asthma guidelines (or both) involving children. </p> </section> <section id="CD011439-sec-0005"> <h3 class="title" id="CD011439-sec-0005">Data collection and analysis</h3> <p>We reviewed results of searches against predetermined criteria for inclusion. Two review authors independently selected relevant studies, assessed trial quality and extracted data. We contacted study authors for further information with responses provided from three. </p> </section> <section id="CD011439-sec-0006"> <h3 class="title" id="CD011439-sec-0006">Main results</h3> <p>The review included nine studies; these studies differed in a variety of ways including definition of asthma exacerbations, FeNO cut‐off levels used (12 parts per billion (ppb) to 30 ppb), the way in which FeNO was used to adjust therapy and duration of study (6 to 12 months). Of 1426 children randomised, 1329 completed the studies. The inclusion criteria for the participants in each study varied but all had a diagnosis of asthma. There was a significant difference in the number of children having one or more asthma exacerbations over the study period, they were significantly lower in the FeNO group in comparison to the control group (odds ratio (OR) 0.62, 95% confidence interval (CI) 0.49 to 0.80; 1279 participants; 8 studies). The number needed to treat for an additional beneficial outcome (NNTB) over 52 weeks was 10 (95% CI 7 to 20). There was no difference between the groups when comparing exacerbation rates (mean difference (MD) ‐0.37, 95% CI ‐0.8 to 0.06; 736 participants; 4 studies; I<sup>2</sup> = 67%). The number of children in the FeNO group requiring oral corticosteroid courses was lower in comparison to the children in the control group (OR 0.63, 95% CI 0.48 to 0.83; 1169 participants; 7 studies; I<sup>2</sup> = 0%). There was no statistically significant difference between the groups for exacerbations requiring hospitalisation (OR 0.75, 95% CI 0.41 to 1.36; 1110 participants; 6 studies; I<sup>2</sup> = 0%). There were no significant differences between the groups for any of the secondary outcomes (forced expiratory volume in one second (FEV<sub>1</sub>), FeNO levels, symptom scores or inhaled corticosteroid doses at final visit). The included studies recorded no adverse events. </p> <p>Three studies had inadequate blinding and were thus considered to have a high risk of bias. However, when these studies were removed in subgroup analysis, the difference between the groups for the primary outcome (exacerbations) remained statistically significant. The GRADE quality of the evidence ranged from moderate (for the outcome 'Number of participants who had one or more exacerbations over the study period') to very low (for the outcome 'Exacerbation rates'), based on lack of blinding, statistical heterogeneity and imprecision. </p> </section> <section id="CD011439-sec-0007"> <h3 class="title" id="CD011439-sec-0007">Authors' conclusions</h3> <p>In this updated review with five new included studies, tailoring asthma medications based on FeNO levels (in comparison with primarily guideline management) significantly decreased the number of children who had one or more exacerbations over the study period but did not impact on the day‐to‐day clinical symptoms or inhaled corticosteroid doses. Therefore, the use of FeNO to guide asthma therapy in children may be beneficial in a subset of children, it cannot be universally recommended for all children with asthma. </p> <p>Further RCTs need to be conducted and these should encompass different asthma severities, different settings including primary care and less affluent settings, and consider different FeNO cut‐offs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011439-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011439-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011439-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011439-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011439-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011439-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011439-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011439-abs-0004" lang="en"> <h3>Can exhaled nitric oxide be used to adjust asthma medications in children with asthma?</h3> <p><b>Background</b> </p> <p>We investigated whether exhaled (breathing out) nitric oxide (a marker in the breath which can show a type of lung inflammation) can be useful to adjust asthma medications in children with asthma instead of following the usual ways that asthma medications are adjusted to get the best dose to control the asthma. Exhaled nitric oxide levels are easily obtained by getting the person to breathe into a commercially available analyser. </p> <p><b>Study characteristics</b> </p> <p>We included all randomised controlled trials that compared adjustment of asthma medications by either usual clinical care (control group) versus using exhaled nitric oxide. The participants included in the trials had asthma diagnosed as per relevant asthma guidelines. </p> <p>The evidence is current to June 2016 when the searches were last completed.</p> <p>The review included nine studies (involving 1426 children) that varied in a several ways including length of the study, exhaled nitric oxide cut‐off levels used for altering medicines and the way each study defined flare‐ups or attacks (called exacerbations). The studies ranged from 6 to 12 months in length. The exhaled nitric oxide cut‐off values used by the different studies as a basis for decreasing or increasing medicines also varied. </p> <p>The mean age of the participants ranged from 10 to 14 years old.</p> <p><b>Key results</b> </p> <p>In this review, we found that guiding asthma medicines based on exhaled nitric oxide (compared to a control group) was beneficial in reducing the number of children who had at least one exacerbation during the study. In the control group where therapy was guided according to clinical symptoms, 40 children out of 100 had at least one exacerbation over 48.5 weeks, compared to 28 out of 100 children where treatment was guided by exhaled nitric oxide. However, we found no difference between groups in other measures of asthma severity that impact on day‐to‐day clinical symptoms or inhaled corticosteroid dose (medications used to control asthma). Therefore, using exhaled nitric oxide levels to adjust asthma therapy may reduce the number of attacks that children with asthma have but does not impact on the day‐to‐day symptoms. </p> <p><b>Quality of the evidence</b> </p> <p>The level of evidence found ranged from moderate, when comparing the two groups for the number of children who had one or more exacerbations, to very low when comparing the number of exacerbations. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011439-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-sec-0115">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-sec-0183">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011439-sec-0115"></div> <h3 class="title" id="CD011439-sec-0116">Implications for practice</h3> <section id="CD011439-sec-0116"> <p>This review has demonstrated that tailoring asthma medications based on exhaled nitric oxide (FeNO) levels significantly reduces the number of children with one or more exacerbation (defined as any exacerbation or rescue oral corticosteroid courses but not hospitalisations) during the study period. However, use of the FeNO strategy was not beneficial for exacerbation rates, or the secondary outcomes of forced expiratory volume in one second (FEV<sub>1</sub>), FeNO levels, inhaled corticosteroid doses or symptom scores. Exacerbation rates were only significantly different between groups when the less appropriate fixed‐effect model was applied to this outcome. </p> <p>Thus, the use of FeNO to guide therapy decisions for medication children with asthma cannot be universally advocated. The intervention may be most useful in a subset of children with asthma. </p> </section> <h3 class="title" id="CD011439-sec-0117">Implications for research</h3> <section id="CD011439-sec-0117"> <p>Further double‐blind, parallel group, randomised controlled trials are required. Studies should be conducted in primary care and consider various cut‐offs for FeNO levels and other significant influences of FeNO levels such as atopy, sex and ethnicity. A 'one size fits all' approach in relation to FeNO levels may not be providing a clear picture. The effect of tailoring asthma medications based on different levels of asthma severity should also be considered. Further cost analyses and adverse events of inhaled and oral corticosteroids would provide additional important information. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011439-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011439-sec-0036"></div> <div class="table" id="CD011439-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tailoring asthma treatment using fractional exhaled nitric oxide versus clinical symptoms</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with asthma<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> asthma treatment tailored on FeNO<br/> <b>Comparison:</b> asthma treatment tailored on clinical symptoms </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clinical symptoms</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with asthma treatment tailored on FeNO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants who had ≥ 1 exacerbations over study period</p> <p>(48.5 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 100<br/> (25 to 35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.62<br/> (0.49 to 0.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1279<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of asthma exacerbations per 52 weeks (exacerbation rate)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of asthma exacerbations per 52 weeks (exacerbation rate) was 1.66</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of asthma exacerbations per 52 weeks (exacerbation rate) in the intervention group was 0.37 lower (0.8 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.37 (‐0.8 to 0.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>736<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS dose at final visit (budesonide equivalent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ICS dose at final visit (budesonide equivalent) was <b>483 μg/day</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ICS dose at final visit (budesonide equivalent) in the intervention group was 63.95 μg/day higher (51.89 lower to 179.79 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FeNO:</b> fractional exhaled nitric oxide; <b>ICS:</b> inhaled corticosteroid; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Three studies carrying 23.7% of the analysis weight were at high risk of performance bias and detection bias due to the lack of blinding (downgraded one level risk of bias) (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> <p><sup>2</sup>One study carrying 11% of the analysis weight was open labelled which may have introduced detection bias (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). A random‐effects sensitivity analysis substantially changed the result to MD ‐0.37 (95% CI ‐0.8 to 0.06). There was also statistical heterogeneity in the analysis (I<sup>2</sup> = 67%, P = 0.03) (downgrade three levels for risk of bias, imprecision and heterogeneity). </p> <p><sup>3</sup>One study carrying 47% of the analysis weight was single blinded and participants were aware of their allocation group (downgraded one level for performance bias) (<a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011439-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-sec-0146">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011439-sec-0037"></div> <section id="CD011439-sec-0038"> <h3 class="title" id="CD011439-sec-0038">Description of the condition</h3> <p>Asthma is one of the most common chronic diseases in children. Acute attacks (exacerbations) are common in children with asthma and some require more intensive treatment in hospital. Hospitalisations for asthma account for 12% to 21% (<a href="./references#CD011439-bbs2-0030" title="AndersonHR , GuptaR , StrachanDP , LimbES . 50 years of asthma: UK trends from 1955 to 2004. Thorax2007;62(1):85‐90. [DOI: 10.1136/thx.2006.066407] ">Anderson 2007</a>; <a href="./references#CD011439-bbs2-0029" title="AkinbamiLJ , MoormanJE , GarbePL , Sondik , EJ . Status of childhood asthma in the United States, 1980‐2007. Pediatrics2009;123(Suppl 3):S131‐45. [DOI: 10.1542/peds.2008‐2233C] ">Akinbami 2009</a>) of hospitalisations worldwide (<a href="./references#CD011439-bbs2-0041" title="GuptaR , AndersonHR , StrachanDP , MaierW , WatsonL . International trends in admissions and drug sales for asthma. International Journal of Tuberculosis and Lung Disease2006;10(2):138‐45. ">Gupta 2006</a>). Thus, prevention of exacerbations, particularly severe exacerbations, is one goal of good asthma management. The second component in asthma management is monitoring of asthma control (by subjective and objective measures) (<a href="./references#CD011439-bbs2-0046" title="National Asthma Council Australia, Melbourne , 2014 . Australian asthma handbook, Version 1.0. www.nationalasthma.org.au/handbook (accessed 31 October 2014). ">National Asthma Council 2014</a>; <a href="./references#CD011439-bbs2-0033" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. www.sign.ac.uk/pdf/SIGN153.pdf (accessed 13 October 2016). ">BTS/SIGN 2016</a>; <a href="./references#CD011439-bbs2-0038" title="Global Initiative forAsthma . Global strategy for asthma management and prevention, 2016. ginasthma.org/2016‐gina‐report‐global‐strategy‐for‐asthma‐management‐and‐prevention (accessed 2 August 2016). ">GINA 2016</a>). Subjective measures usually involve a series of questions used for clinical assessment, diary cards and quality of life (QoL) questionnaires. Traditional objective methods include peak flow, spirometry and degree of airway hyper‐responsiveness (<a href="./references#CD011439-bbs2-0027" title="ZacharasiewiczA , WilsonN , LexC , ErinEM , LiAM , HanselT , et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. American Journal of Respiratory and Critical Care Medicine2005;171(10):1077‐82. [DOI: 10.1164/rccm.200409‐1242OC] ">Zacharasiewicz 2005</a>). Newer and arguably more sensitive methods include measurement of airway inflammation such as airway cellularity in induced sputum or fractional exhaled nitric oxide (FeNO). </p> <p>Airway inflammation associated with asthma can be eosinophilic or neutrophilic (<a href="./references#CD011439-bbs2-0035" title="DouwesJ , GibsonP , PekkanenJ , PearceN . Non‐eosinophilic asthma: importance and possible mechanisms. Thorax2002;57(7):643‐8. ">Douwes 2002</a>). Arguably, asthma management is best tailored in accordance to the type of airway inflammation, as corticosteroids are more beneficial in eosinophilic inflammation (<a href="./references#CD011439-bbs2-0050" title="WardlawAJ , BrightlingC , GreenR , WoltmannG , PavordI . Eosinophils in asthma and other allergic diseases. British Medical Bulletin2000;56(4):985‐1003. ">Wardlaw 2000</a>); inhaled corticosteroids (ICS) reduce exacerbations and improve symptoms and asthma control (<a href="./references#CD011439-bbs2-0050" title="WardlawAJ , BrightlingC , GreenR , WoltmannG , PavordI . Eosinophils in asthma and other allergic diseases. British Medical Bulletin2000;56(4):985‐1003. ">Wardlaw 2000</a>). There are several ways to quantify airway eosinophilic inflammation, such as determining the percentage of eosinophils in the sputum and FeNO. FeNO correlates with other markers of asthma, for example, eosinophilia in induced sputum (<a href="./references#CD011439-bbs2-0043" title="JatakanonA , LimS , KharitonovSA , ChungKF , BarnesPJ . Correlation between exhaled nitric oxide, sputum eosinophils and methacholine responsiveness in patients with mild asthma. Thorax1998;53(2):91‐5. ">Jatakanon 1998</a>), and bronchial reactivity in non‐steroid treated people (<a href="./references#CD011439-bbs2-0036" title="DupontLJ , RochetteF , DemedtsMG , VerledenGM . Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid‐naive patients with mild asthma. American Journal of Respiratory and Critical Care Medicine1998;157(3 (pt 1)):894‐8. ">Dupont 1998</a>). </p> </section> <section id="CD011439-sec-0039"> <h3 class="title" id="CD011439-sec-0039">Description of the intervention</h3> <p>The principle of asthma management is based on a step‐up or step‐down regimen of asthma medications to reduce airway inflammation, control symptoms and reduce exacerbations. Therefore, tailoring of asthma medications in accordance to levels reflective of airway eosinophilia may improve asthma control or reduce exacerbations, or both. Obtaining induced sputum samples and sputum analysis is labour intensive and not widely available in most routine clinical settings. Hypertonic saline, used to induce sputum may also temporarily increase asthma symptoms (such as wheeze, cough and chest tightness) and sputum is not always successfully obtained in young children. Thus, measures of FeNO confer some advantage over measurements of sputum eosinophils. However, assessment of FeNO levels do not provide any data on non‐eosinophilic inflammation and the equipment required to measure FeNO is relatively expensive. </p> <p>FeNO levels can be measured using commercially available analysers. These analysers vary in several ways that include methods of measurements (online or offline), complexity, setup, calibration procedures, sampling tube design, measuring chamber and the way expiratory flow is controlled (<a href="./references#CD011439-bbs2-0045" title="MüllerKC , JorresRA , MagnussenH , HolzO . Comparison of exhaled nitric oxide analysers. Respiratory Medicine2005;99(5):631‐7. ">Müller 2005</a>). The stationary analysers measure FeNO by chemoluminescence whilst the portable FeNO analysers measure FeNO using electrochemistry. </p> </section> <section id="CD011439-sec-0040"> <h3 class="title" id="CD011439-sec-0040">How the intervention might work</h3> <p>As FeNO is reflective of airway eosinophilia in some circumstances, FeNO can be considered as a biomarker. For asthma, FeNO levels can potentially be used in children with asthma to: </p> <p> <ul id="CD011439-list-0001"> <li> <p>monitor airway eosinophilia;</p> </li> <li> <p>verify the adherence to ICS; and</p> </li> <li> <p>predict upcoming asthma exacerbations.</p> </li> </ul> </p> <p>Reduction of airway inflammation improves symptoms and asthma control (<a href="./references#CD011439-bbs2-0050" title="WardlawAJ , BrightlingC , GreenR , WoltmannG , PavordI . Eosinophils in asthma and other allergic diseases. British Medical Bulletin2000;56(4):985‐1003. ">Wardlaw 2000</a>). Hence, the use of FeNO levels to tailor asthma medications in children with asthma may improve asthma control or reduce exacerbations, or both. </p> </section> <section id="CD011439-sec-0041"> <h3 class="title" id="CD011439-sec-0041">Why it is important to do this review</h3> <p>A previous Cochrane Review included both adults and children (<a href="./references#CD011439-bbs2-0051" title="PetskyHL , CatesCJ , LiA , KynastonJA , TurnerC , ChangAB . Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006340.pub3] ">Petsky 2009</a>). Given the clinical heterogeneity between children and adults with asthma, rather than update that review, we undertook separate reviews for children and adults. This review focuses on children and there is a similar systematic review that includes only adults (<a href="./references#CD011439-bbs2-0048" title="PetskyHL , KewKM , TurnerC , ChangAB . Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD011440.pub2] ">Petsky 2016</a>). </p> <p>A systematic review evaluating the efficacy of tailoring asthma interventions based on FeNO levels will be useful to guide clinical practice in children with asthma. Using FeNO routinely in clinical practice adds to the burden of asthma care and resource utilisation. In addition, routine use of FeNO to guide use of asthma medications may improve asthma control and reduce exacerbations and hospitalisations related to asthma. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011439-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-sec-0151">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011439-sec-0042"></div> <p>To evaluate the efficacy of tailoring asthma medications based on fractional exhaled nitric oxide (FeNO), in comparison to not using FeNO, that is, management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines (or both), for asthma‐related outcomes in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011439-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-sec-0152">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011439-sec-0043"></div> <section id="CD011439-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011439-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing adjustment of asthma medications based on FeNO levels in comparison to those not using FeNO, that is, management based on clinical symptoms (with or without spirometry/peak flow) or current asthma guidelines, or both. We included studies reported as full‐text, abstract only, and unpublished data. </p> </section> <section id="CD011439-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included children/adolescents with a diagnosis of asthma according to guideline‐defined criteria. </p> <p>We excluded participants with the following comorbidities/characteristics: eosinophilic bronchitis, asthma related to an underlying lung disease such as bronchiectasis and chronic obstructive pulmonary disease or diagnostic categories such as 'cough variant asthma' and 'wheezy bronchitis'. </p> </section> <section id="CD011439-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We included RCTs comparing adjustment of asthma medications based on FeNO levels versus control groups where FeNO is not used to adjust asthma medications. Control group interventions may have included use of clinical symptoms (with or without spirometry/peak flow) to guide adjustment of asthma medications. Studies that included the use of other interventions were included if all participants had equal access to such interventions. We included trials of at least 12 weeks' duration. </p> </section> <section id="CD011439-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD011439-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011439-list-0002"> <li> <p>Asthma exacerbations during follow‐up defined as:</p> <ul id="CD011439-list-0003"> <li> <p>number of participants who had one or more exacerbation over the study period;</p> </li> <li> <p>number of exacerbations per 52 weeks (exacerbation rate);</p> </li> <li> <p>severe exacerbations requiring oral corticosteroids;</p> </li> <li> <p>severe exacerbation requiring hospitalisations.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD011439-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011439-list-0004"> <li> <p>Objective measurements of asthma control (forced expiratory volume in one second (FEV<sub>1</sub>), peak flow, airway hyper‐responsiveness). </p> </li> <li> <p>FeNO level.</p> </li> <li> <p>Symptoms of asthma as reported in asthma QoL score.</p> </li> <li> <p>ICS dose at final visit.</p> </li> </ul> </p> <p>Reporting one or more of the outcomes listed here was not an inclusion criteria for this review. </p> </section> </section> </section> <section id="CD011439-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011439-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We identified studies from the Cochrane Airways Group's Specialised Register (CAGR), which is maintained by the Information Specialist for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD011439-sec-0121">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy in <a href="./appendices#CD011439-sec-0127">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the World Health Organization (WHO) trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). We searched all databases from their inception to the present, and we imposed no restriction on language of publication. All searches were undertaken by the Cochrane Airways Group central team (by Elizabeth Stovold) and the latest search was undertaken on 30 June 2016. </p> </section> <section id="CD011439-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for trial information. </p> <p>We searched for errata or retractions from included studies published in full‐text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>), and reported the date this was done within the review. </p> </section> </section> <section id="CD011439-sec-0054"> <h3 class="title" id="CD011439-sec-0054">Data collection and analysis</h3> <section id="CD011439-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HP, KK) independently screened titles and abstracts for inclusion of all the potential studies we identified with the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We then retrieved the full‐text study reports/publication and two review authors (HP, KK) independently screened the full‐text and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We planned to resolve any disagreement through discussion or, if required, consult a third review author (AC). We identified and excluded duplicates and collate multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete the PRISMA flow diagram and <a href="./references#CD011439-sec-0144" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011439-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data which was piloted on at least one study in the review. One review author (HP) extracted study characteristics from included studies. A second review author (KK) spot‐checked study characteristics for accuracy against the trial report. We then extracted the following study characteristics. </p> <p> <ul id="CD011439-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (HP, KK) independently extracted outcome data from included studies from current search. We noted in the <a href="./references#CD011439-sec-0143" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by involving a third review author (AC). One review author (HP) transferred data into Review Manager 5 (<a href="./references#CD011439-bbs2-0049" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. </p> </section> <section id="CD011439-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HP, KK) independently assessed risk of bias for each new study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011439-bbs2-0042" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We planned to resolve any disagreements by discussion or by involving another review author (AC). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD011439-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We then summarised the risk of bias judgements across different studies for each of the domains listed. We planned to blind separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different from for a participant‐reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we considered the risk of bias for the studies that contributed to that outcome. </p> <section id="CD011439-sec-0058"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD011439-sec-0141">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD011439-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (OR) and continuous data as mean difference (MD) or standardised mean difference (SMD) with 95% confidence intervals (CI). We then entered data presented as a scale with a consistent direction of effect. </p> <p>We undertook meta‐analyses only where it was meaningful (i.e. if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense). </p> <p>We narratively described skewed data reported as medians and interquartile ranges.</p> <p>Where multiple trial arms were reported in a single trial, we included only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD011439-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous data, we reported the proportion of participants contributing to each outcome in comparison with the total number randomised. For rate ratios of common events whereby one participant may have more than one event, we used generic inverse variance (GIV) analysis. The rate ratios were taken from the published papers and the standard errors calculated from CIs or P values published in the papers. We had planned for cross‐over studies, to calculate the mean treatment differences from raw data, and variances extracted or imputed and entered as a fixed‐effect (GIV) outcome, to provide summary weighted differences and 95% CIs. </p> </section> <section id="CD011439-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD011439-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We described any heterogeneity between the study results and tested it to see if it reached statistical significance using a Chi<sup>2</sup> test. We planned to include the 95% CI estimated using a random‐effects model whenever there were concerns about statistical heterogeneity. Heterogeneity was considered significant when the P value is less than 0.10 (<a href="./references#CD011439-bbs2-0042" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We then used the I<sup>2</sup> statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity, we reported it and explored possible causes by prespecified subgroup analysis. </p> </section> <section id="CD011439-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>We were unable to pool more than 10 trials, so did not create and examine a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD011439-sec-0064"> <h4 class="title">Data synthesis</h4> <p>We included the results from studies that met the inclusion criteria and reported any of the outcomes of interest in the subsequent meta‐analyses. We calculated the summary weighted RR and 95% CI (fixed‐effect model) using Review Manager 5 (<a href="./references#CD011439-bbs2-0049" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For rate ratios of common events whereby one participant may have more than one event, we used GIV. The rate ratios were taken from the published papers and the standard errors calculated from CIs or P values published in the papers. For cross‐over studies, we planned to calculate the mean treatment differences from raw data, and extract or impute variances and enter them as fixed‐effect GIV outcomes, to provide summary weighted differences and 95% CI. Numbers needed to treat were calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (<a href="./references#CD011439-bbs2-0034" title="Dr Christopher Cates. Visual Rx. Online NNT calculator. http://www.nntonline.net/. Dr Christopher Cates, 2008. ">Cates 2008</a>). The outcome indices were assumed to be normally distributed continuous variables so the MDs in outcomes could be estimated. If studies reported outcomes using different measurement scales, we estimated the SMD. </p> <section id="CD011439-sec-0065"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following outcomes:</p> <p> <ul id="CD011439-list-0007"> <li> <p>number of participants who had one or more exacerbations over the study period;</p> </li> <li> <p>number of asthma exacerbations per 52 weeks,</p> </li> <li> <p>ICS dose at final visit.</p> </li> </ul> </p> <p>The 'Summary of findings' table in the previous combined review (<a href="./references#CD011439-bbs2-0051" title="PetskyHL , CatesCJ , LiA , KynastonJA , TurnerC , ChangAB . Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006340.pub3] ">Petsky 2009</a>) was amended to reflect new data and restricted to the inclusion criteria. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We then used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011439-bbs2-0042" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD011439-bbs2-0040" title="GRADE Working Group, McMaster University. GRADEpro GDT. GRADE Working Group, McMaster University, 2015. ">GRADEpro GDT 2015</a>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes and we made comments to aid reader's understanding of the review where necessary. </p> </section> </section> <section id="CD011439-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses:</p> <p> <ul id="CD011439-list-0008"> <li> <p>basis for adjustment of ICS in the control group (guideline driven monitoring versus non‐guideline driven); </p> </li> <li> <p>use of spirometry or peak flow as an adjunctive monitoring tool for adjustment of medications versus non‐use of spirometry or peak flow; </p> </li> <li> <p>baseline ICS dose at commencement of intervention (low‐medium (&lt; 800 μg/day of budesonide equivalent) versus high dose (800 μg/day or more of budesonide equivalent); </p> </li> <li> <p>FeNO cut‐offs for adjustment of medications (20 parts per billion (ppb) or less versus more than 20 ppb); </p> </li> <li> <p>FeNO cut‐offs, based on presence of atopy.</p> </li> </ul> </p> </section> <section id="CD011439-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out the following sensitivity analyses.</p> <p> <ul id="CD011439-list-0009"> <li> <p>Sensitivity analysis excluding studies with a high risk of bias based on the 'Risk of bias' assessment. We removed studies that did not have adequate allocation concealment and sequence generation. </p> </li> <li> <p>Variation in the inclusion criteria. We removed studies that included children not receiving ICS at recruitment. </p> </li> <li> <p>Differences in the medications used in the intervention and comparison group. We removed studies that adjusted medications only for one arm. </p> </li> <li> <p>Analysis comparing the random‐effects model to a fixed‐effect model.</p> </li> <li> <p>Analysis by 'strategy received'. We removed studies with hierarchy management protocols that only considered use of steroids for each step (i.e. without consideration for using montelukast or long‐acting beta‐agonist (LABA), or both, at any point). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011439-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011439-sec-0068"></div> <section id="CD011439-sec-0069"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD011439-sec-0143" title="">Characteristics of included studies</a>; <a href="./references#CD011439-sec-0144" title="">Characteristics of excluded studies</a>; <a href="./references#CD011439-sec-0145" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD011439-sec-0070"> <h4 class="title">Results of the search</h4> <p>From the searches, the CAGR identified 1084 potentially relevant titles (<a href="#CD011439-fig-0001">Figure 1</a>). We identified an additional 129 titles through searches of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the WHO trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). After assessing the abstracts, we obtained 30 papers for consideration after removing duplicates. We excluded 14 papers due to non‐randomisation or treatment not being based on FeNO. Of the potential 16 papers, nine included children or adolescents and the remaining seven were based on adults, which are presented in a separate Cochrane Review <i>(</i><a href="./references#CD011439-bbs2-0048" title="PetskyHL , KewKM , TurnerC , ChangAB . Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD011440.pub2] ">Petsky 2016</a>). </p> <div class="figure" id="CD011439-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Prisma flow diagram." data-id="CD011439-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prisma flow diagram.</p> </div> </div> </div> </section> <section id="CD011439-sec-0071"> <h4 class="title">Included studies</h4> <p>The review included nine studies (see <a href="./references#CD011439-sec-0143" title="">Characteristics of included studies</a>). The nine studies involved 1426 randomised participants with 1329 completing the trials (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). Of these nine studies, five were new (i.e. were not in the previous (<a href="./references#CD011439-bbs2-0051" title="PetskyHL , CatesCJ , LiA , KynastonJA , TurnerC , ChangAB . Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006340.pub3] ">Petsky 2009</a>) review). </p> <section id="CD011439-sec-0072"> <h5 class="title">Study design</h5> <p>All nine studies were parallel‐group studies. Five were multicentre studies (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), one was dual centre (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), and three were single‐centre studies (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). </p> <p>One study used a three‐arm strategy to adjust ICS (<a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). The strategy arms were: web group, where treatment was adjusted monthly based on the web‐based Asthma Control Test (ACT) score; FeNO group, where treatment was adjusted according to FeNO and ACT score at four‐monthly clinic visits; or standard care, where treatment was adjusted according to the ACT score during clinic visits. For this review, we considered the FeNO with ACT score strategy arm as the intervention group and the standard care strategy as the control group. </p> <p>Of the nine studies; four were double blind (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), three were single blind (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), and two had no blinding (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). </p> <p>The study duration varied ranging from 6 to 12 months (<a href="#CD011439-tbl-0002">Table 1</a>). Each study defined exacerbations differently (<a href="#CD011439-tbl-0002">Table 1</a>). </p> <div class="table" id="CD011439-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies definitions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exacerbation definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FeNO strategy (FeNO levels in ppb)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom strategy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided</p> <p>(OCS courses and hospitalisation data included</p> <p>in exacerbation results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In children aged 6 to 10 years:</p> <p>&lt; 20 and ≤ 60 symptom score = step down/discontinue</p> <p>&gt; 20 and ≤ 60 symptom score = increase</p> <p>&lt; 20 and &gt; 60 symptom score = no change</p> <p>&gt; 20 and &gt; 60 symptom score = step up</p> <p>In children aged &gt; 10 years:</p> <p>&lt; 25 and ≤ 60 symptom score = step down/discontinue</p> <p>&gt; 25 and ≤ 60 symptom score = increase</p> <p>&lt; 25 and &gt; 60 symptom score = no change</p> <p>&gt; 25 and &gt; 60 symptom score = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Below range (&lt; 10) = step down/discontinue</p> <p>In range (10 to 60) = no change</p> <p>Above range (&gt; 60) = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 parameters:</p> <p>OCS because of asthma symptoms,</p> <p>non‐scheduled visit because of asthma</p> <p>symptoms, &gt; symptom score to 2,</p> <p>&lt; FEV<sub>1</sub> (in litres) &gt; 10% compared to </p> <p>previous visit, or a combination of these</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 20 and FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = step down</p> <p>≤ 20 and FEV<sub>1</sub> &lt; 80% or symptoms score &gt; 1 or SABA </p> <p>use ≥ 6 = step up</p> <p>Participant on SABA on demand only:</p> <p>&gt; 20 and FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = step up</p> <p>Participant on ICS:</p> <p>&gt; 20 and FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = same step</p> <p>&gt; 20 and FEV<sub>1</sub> &lt; 80% or symptoms score &gt; 1 or SABA </p> <p>use ≥ 6 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austrian asthma guidelines:</p> <p>FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = step down</p> <p>FEV<sub>1</sub> &lt; 80% or symptoms score &gt; 1 or SABA </p> <p>use ≥ 6 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As per GINA guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 20 and controlled = step down</p> <p>≤ 20 and partially controlled consider LTRA</p> <p>&gt; 20 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GINA guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory events requiring OCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elevated FeNO = step up</p> <p>Low FeNO for 2 visits = step down</p> <p>Elevated FeNO defined as:</p> <p>≥ 10 with no positive SPT</p> <p>≥ 12 with 1 positive SPT</p> <p>≥ 20 with ≥ 2 positive SPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma symptom diary card</p> <p>Score &lt; 10 in previous week = step down</p> <p>Score increased ≥ 15% since previous week</p> <p>= step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided</p> <p>(OCS courses included in results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 30 and symptom score ≤ 14 = step down</p> <p>≤ 30 and symptom score &gt; 14 = no change</p> <p>&gt; 30, regardless of symptoms = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≤ 14 second time = step down</p> <p>Symptom score ≤ 14 first time = no change</p> <p>Symptom score &gt; 14 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 48 hours &gt; asthma symptoms or therapy or &lt; PEF (≥25%).</p> <p>Mild: increase SABA only</p> <p>Moderate: requiring systemic corticosteroids</p> <p>Severe: requiring hospitalisations ≥ 8 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 15 and well controlled = step down</p> <p>&lt; 25 and poorly controlled = LABA maximised</p> <p>≥ 25 or FeNO doubled from baseline = step up</p> <p>If FeNO remained raised after 2 x steps (SIGN/BTS</p> <p>steps) ICS not increased again unless participant</p> <p>poorly controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIGN/BTS guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admissions to hospital, unscheduled visits and</p> <p>prednisone use for asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NHLBI guidelines and FeNO</p> <p>≤ 20 and Level 1 = no change</p> <p>20.1 to 30 and Level 2 = step up</p> <p>30.1 to 40 and Level 3 = 2 steps</p> <p>&gt; 40 and Level 4 = 3 steps or 2 steps and OCS course</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NHLBI guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>According to ATS/ERS criteria and requiring<br/> SABA. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 month visit only:</p> <p>&lt; 12 = step down or no change</p> <p>&gt; 12 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As per GINA:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided</p> <p>(OCS courses and hospitalisation data included</p> <p>in exacerbation results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If ACT ≥ 20 and:</p> <p>FeNO &lt; 25 = step down</p> <p>FeNO ≥ 25 to &lt; 50 = no change</p> <p>FeNO ≥ 50 = step up</p> <p>If ACT &lt; 20 and:</p> <p>FeNO ≥ 25 = step up</p> <p>FeNO &lt; 25 = no change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACT results:</p> <p>&lt; 20 = step up</p> <p>≥ 20 = no change or step</p> <p>down</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACT: Asthma Control Test; ATS: American Thoracic Society; BTS: British Thoracic Society; ERS: European Respiratory Society; FeNO: fractional exhaled nitric oxide; FEV<sub>1</sub>: forced expiratory volume in first second; GINA: Global initiative for asthma; ICS: inhaled corticosteroids; LTRA: leukotriene receptor antagonist; NHLBI: National Heart, Lung, and Blood Institute; OCS: oral corticosteroids; ppb: parts per billion; SABA: short‐acting beta<sub>2</sub> agonist; SIGN: Scottish Intercollegiate Guidelines Network; SPT: skin prick test. </p> </div> </div> </section> <section id="CD011439-sec-0073"> <h5 class="title">Participants</h5> <p>The nine studies had different inclusion criteria for the participants. All studies included participants with asthma which was defined as per current guidelines. </p> </section> <section id="CD011439-sec-0074"> <h5 class="title">Fractional exhaled nitric oxide strategy</h5> <p>The intervention arm in all nine studies, although primarily based on FeNO level, differed in the cut‐off for FeNO for change in therapy. <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a> was the only study which utilised different cut‐offs for the presence of atopy. </p> <p>The FeNO cut‐offs used for the studies are presented in <a href="#CD011439-tbl-0002">Table 1</a>. </p> </section> <section id="CD011439-sec-0075"> <h5 class="title">Control group</h5> <p>Five of the nine studies utilised existing asthma guidelines to adjust treatment in the control group (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>). Three studies used participant‐reported symptoms (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), and one utilised the Asthma Control Questionnaire (ACQ) (<a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). The control group strategies are described in <a href="#CD011439-tbl-0002">Table 1</a>. </p> </section> <section id="CD011439-sec-0076"> <h5 class="title">Outcomes</h5> <p>The primary outcomes of the studies also varied. Three studies used symptom‐free days (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), three studies used asthma exacerbations (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), three studies included ICS cumulative doses (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>), one study used number of days with symptoms (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>), and another used FEV<sub>1</sub> (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>). The definitions of exacerbations were different among the studies (<a href="#CD011439-tbl-0002">Table 1</a>). </p> <p>The secondary outcomes also varied between the studies. Four studies included asthma exacerbations (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), four studies used dose of ICS (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), three studies included spirometry (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), and <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a> and <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a> used asthma QoL questionnaires. </p> <p>We contacted study authors to request further data, or data that could be included in the meta‐analysis; three study authors provided data (<a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> <p>The study characteristics are described in the <a href="./references#CD011439-sec-0143" title="">Characteristics of included studies</a> table. </p> </section> </section> <section id="CD011439-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We recorded the reasons for excluding the 20 studies in the <a href="./references#CD011439-sec-0144" title="">Characteristics of excluded studies</a> table. The most common reasons for exclusion were: not an RCT (seven studies), treatment not adjusted according to FeNO (six studies), and population was not children or adolescents (seven studies). One further study was found in abstract form only (<a href="./references#CD011439-bbs2-0028" title="Duong‐QuyS , Hua‐HuyT , Doan‐QuynhN , Nguyen‐QuocB , Le‐QuangK , Tran‐ThanhD , et al. A study of exhaled NO (FeNO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country. European Respiratory Journal2015;46(Suppl 59):PA5013. ">Duong‐Quy 2015</a>). We contacted this study author in January 2016 and they confirmed that the paper is in preparation, therefore this study was judged to be ongoing and will be included in the next update (<a href="./references#CD011439-bbs2-0028" title="Duong‐QuyS , Hua‐HuyT , Doan‐QuynhN , Nguyen‐QuocB , Le‐QuangK , Tran‐ThanhD , et al. A study of exhaled NO (FeNO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country. European Respiratory Journal2015;46(Suppl 59):PA5013. ">Duong‐Quy 2015</a>). </p> </section> </section> <section id="CD011439-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p>The full details of risk of bias judgements is described under the 'Risk of Bias' section in the <a href="./references#CD011439-sec-0143" title="">Characteristics of included studies</a> table and is summarised in <a href="#CD011439-fig-0002">Figure 2</a>. Overall, the methodological quality of the included studies was good. </p> <div class="figure" id="CD011439-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011439-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011439-sec-0079"> <h4 class="title">Allocation</h4> <p>Four studies described generation of randomisation sequence (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), and it was unclear in five studies (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>). The method of allocation concealment was adequate in four studies (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), and unclear in five (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> </section> <section id="CD011439-sec-0080"> <h4 class="title">Blinding</h4> <p>Risk associated with participant blinding was low when the blinding of the assessors was reported based on information provided by authors of the studies. These included comments from the studies such as "a third party provided advice on treatment decisions" and "both arms of the study received the same follow‐up including measurements and tests". </p> <p>Risk of detection bias due to inadequate blinding of outcome assessors was high in three studies (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), and unclear in one study (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>), as there was not enough information in the published article. Five studies were at low risk of bias (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). </p> </section> <section id="CD011439-sec-0081"> <h4 class="title">Incomplete outcome data</h4> <p>Five studies were at low risk of attrition bias (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). Three studies were at high risk of attrition bias as they reported unbalanced dropout rates (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>). <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a> did not report on dropouts and was therefore judged at unclear risk of attrition bias. </p> </section> <section id="CD011439-sec-0082"> <h4 class="title">Selective reporting</h4> <p>Reporting bias was low in two studies with all outcomes being reported (<a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). Three studies were at unclear risk of reporting bias as there was inadequate information in the published articles (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>). Four studies were at high risk of reporting bias as some of the secondary outcomes were not reported or incorrect analyses methods were used (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). </p> </section> <section id="CD011439-sec-0083"> <h4 class="title">Other potential sources of bias</h4> <p>Another source of bias was the success of obtaining FeNO levels at each visit according to current guidelines. Five studies did not report the success of obtaining FeNO at each time point (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). One study reported that they successfully obtained FeNO at each visit (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). Two studies were at high risk as they reported technical problems with the FeNO analysers including 11 out of 77 analysers showing drift in calibration after the study (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>). <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a> was at high risk as they reported not following current guidelines by only doing a single measurement of FeNO at each visit. </p> </section> </section> <section id="CD011439-sec-0084"> <h3 class="title" id="CD011439-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD011439-tbl-0001"><b>Summary of findings for the main comparison</b> Tailoring asthma treatment using fractional exhaled nitric oxide versus clinical symptoms</a> </p> <p>See <a href="./full#CD011439-tbl-0001">summary of findings Table for the main comparison</a> for the main comparisons. </p> <section id="CD011439-sec-0085"> <h4 class="title">Primary outcome: asthma exacerbations</h4> <p>Three studies used asthma exacerbations as their primary outcome but the definition differed among the studies (described in <a href="#CD011439-tbl-0002">Table 1</a>), as did the way the outcome was measured and presented (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). Three studies reported a reduction in asthma exacerbations in the intervention arm compared to the control arm (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). For the various types of exacerbations, we combined data into the meta‐analysis, as described below. </p> <section id="CD011439-sec-0086"> <h5 class="title">1.1 Number of participants who had one or more exacerbations over the study period</h5> <p>See <a href="./references#CD011439-fig-0004" title="">Analysis 1.1</a>. </p> <p>Combined data from eight studies showed that the number of participants experiencing an exacerbation was significantly lower (P = 0.0002) in the FeNO group compared to the control (clinical symptom) group over the study period (OR 0.62, 95% CI 0.49 to 0.8; 1279 participants; 8 studies; I<sup>2</sup> = 21%) (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). There was some statistical heterogeneity among the studies but it was not significant (I<sup>2</sup> = 21%). In the control group where therapy was guided according to clinical symptoms, 40 children out of 100 had at least one exacerbation over 48.5 weeks, compared to 29 (95% CI 25 to 35) out of 100 for those where treatment was guided by FeNO. The number needed to treat to show an additional beneficial outcome (NNTB) over 52 weeks was 10 (95% CI 7 to 20) (<a href="#CD011439-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011439-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="In the control group, 40 children out of 100 had exacerbations over one year, compared to 29 (95% confidence interval (CI) 25 to 35) out of 100 for the active treatment group. Number needed to treat for one additional beneficial outcome = 10 (95% CI 7 to 20)." data-id="CD011439-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the control group, 40 children out of 100 had exacerbations over one year, compared to 29 (95% confidence interval (CI) 25 to 35) out of 100 for the active treatment group. Number needed to treat for one additional beneficial outcome = 10 (95% CI 7 to 20). </p> </div> </div> </div> </section> <section id="CD011439-sec-0087"> <h5 class="title">1.2 Number of exacerbations per 52 weeks (exacerbation rates)</h5> <p>See <a href="./references#CD011439-fig-0005" title="">Analysis 1.2</a>. </p> <p>Combined data from four studies for the outcome of exacerbation rate (over 52 weeks) found no differences between the groups (P = 0.09) (MD ‐0.37, 95% CI ‐0.80 to 0.06; 736 participants; 4 studies) (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). As there was statistical heterogeneity among the studies (I<sup>2</sup> = 67%, P = 0.03), we used a random‐effects analysis. The statistical heterogeneity could be accounted for by the skew in some of the studies data. The rate of exacerbation over the 52 weeks in the control group ranged from 0.78 to 3.2. </p> </section> <section id="CD011439-sec-0088"> <h5 class="title">1.3 Number of participants who had severe exacerbations requiring hospitalisation</h5> <p>See <a href="./references#CD011439-fig-0006" title="">Analysis 1.3</a>. </p> <p>Five studies reported hospitalisations due to worsening of asthma symptoms (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), and another study reported that no participants were hospitalised (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). In the meta‐analysis, there was no significant difference (P = 0.37) between groups; 20 children in the FeNO group versus 26 in the control group required hospitalisation (OR 0.75, 95% CI 0.41 to 1.36; 1110 participants; 6 studies; I<sup>2</sup> = 0%). </p> </section> <section id="CD011439-sec-0089"> <h5 class="title">1.4 Number of participants who had severe exacerbations requiring rescue oral corticosteroids</h5> <p>See <a href="./references#CD011439-fig-0007" title="">Analysis 1.4</a>. </p> <p>Seven studies reported using rescue oral corticosteroids (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). The meta‐analysis showed a significantly fewer children (P = 0.001) in the FeNO group required rescue oral corticosteroids compared to the control group (OR 0.63, 95% CI 0.48 to 0.83; 1169 participants; 7 studies; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD011439-sec-0090"> <h4 class="title">Secondary outcomes</h4> <section id="CD011439-sec-0091"> <h5 class="title">1.5 FEV<sub>1</sub>% predicted at final visit </h5> <p>See <a href="./references#CD011439-fig-0008" title="">Analysis 1.5</a>. </p> <p>We combined the final visit FEV<sub>1</sub>% predicted from seven studies in a meta‐analysis and we found no significant difference between the groups (P = 0.12; MD 1.0, 95% CI ‐0.07 to 2.07; 1181 participants; 7 studies; I<sub>2</sub> = 0%) (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). The two remaining studies reported no significant difference between the two groups, but as details were not provided, we could not include the data in the meta‐analysis (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006;</a><a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). </p> </section> <section id="CD011439-sec-0092"> <h5 class="title">1.6 FeNO geometric mean level at final visit</h5> <p>See <a href="./references#CD011439-fig-0009" title="">Analysis 1.6</a>. </p> <p>We combined the final visit's FeNO geometric mean (GM) from three studies in a meta‐analysis (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). The data were heavily skewed and ratio of GM was the most appropriate analysis to use. There was no significant difference between the groups (GM 0.99, 95% CI 0.87 to 1.11; 414 participants; 3 studies; I<sub>2</sub> = 69%). The remaining six studies could not be included in the meta‐analysis but reported that there was no significant difference between the groups at the final visit (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>, and <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a> reported that there was a decreased trend in FeNO levels for the FeNO group at the final visit but this was not significant. </p> </section> <section id="CD011439-sec-0093"> <h5 class="title">1.7 Symptom score: Asthma Control Test</h5> <p>See <a href="./references#CD011439-fig-0010" title="">Analysis 1.7</a>. </p> <p>Two studies reported ACT results; the meta‐analysis showed no significant difference between groups (MD 0.14, 95% CI ‐0.18 to 0.47; 724 participants; 2 studies; I<sup>2</sup> = 62%) (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> </section> <section id="CD011439-sec-0094"> <h5 class="title">1.8 Symptom score as per Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) </h5> <p>See <a href="./references#CD011439-fig-0011" title="">Analysis 1.8</a>. </p> <p>Combined data from three studies found no significant difference between groups for the PACQLQ (MD 0.09, 95% CI ‐0.08 to 0.27; 380 participants; 3 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> </section> <section id="CD011439-sec-0095"> <h5 class="title">1.9 Inhaled corticosteroid dose at final visit (budesonide equivalent in micrograms per day) </h5> <p>See <a href="./references#CD011439-fig-0012" title="">Analysis 1.9</a>. </p> <p>Three studies reported final ICS doses that could be included in a meta‐analysis; there was no significant difference between the groups (MD 63.95 μg/day, 95% CI ‐51.89 to 179.79; 317 participants; 3 studies; I<sup>2</sup> = 40%) (<a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). Using a random‐effects model, the difference between the groups remained nonsignificant (MD 65.88 μg/day, 95% CI ‐86.71 to 218.47). </p> <p>Four studies reported that there was no difference in daily ICS doses between the groups at the final visit (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>). The remaining two studies reported that the control group had lower doses of ICS at the end of the study (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>). </p> </section> <section id="CD011439-sec-0096"> <h5 class="title">1.10 Cost effectiveness of the intervention</h5> <p>One study (<a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>) published a separate paper (<a href="./references#CD011439-bbs2-0032" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] ">Beerthuizen 2016</a>) assessed the cost of the strategies in their three‐armed trial (standard care, web‐based strategy and FeNO‐based). They reported no significant difference in costs or quality‐adjusted life years between the groups. The web‐based strategy (this arm not included in this systematic review) was 77% more cost effective from a healthcare perspective, whereas the FeNO‐based strategy had an 83% chance of being most cost effective from a societal perspective. </p> </section> </section> <section id="CD011439-sec-0097"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD011439-sec-0098"> <h5 class="title">1. Based on adjustment of inhaled corticosteroid in the control group (guideline‐driven versus others) </h5> <p>When testing for subgroup differences there was no significant difference between the subgroups for either exacerbation outcome (<a href="./references#CD011439-fig-0013" title="">Analysis 1.10</a>; <a href="./references#CD011439-fig-0014" title="">Analysis 1.11</a>). </p> <p>Four of the studies utilised asthma guidelines as the basis of adjusting medications in the control group (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>). In this subgroup, for the primary outcome of number of participants with one or more exacerbations, the significant difference between the groups was still present, favouring the FeNO group (OR 0.67, 95% CI 0.51 to 0.90). In the studies that used other methods for adjusting medications as the control group, also fewer children in the FeNO group had exacerbations compared to the control group (OR 0.55, 95% CI 0.34 to 0.90). Likewise, there was a significant difference between the groups for the outcome of exacerbation rates for the studies where the control groups' management was guideline‐driven (MD ‐0.27, 95% CI ‐0.49 to ‐0.06), as well as for the studies where the control groups' management was not guideline‐driven (i.e. other) (MD ‐0.39, 95% CI ‐0.84 to 0.06). However, there was significant statistical heterogeneity in this subgroup analyses when considering only the guideline‐driven studies. </p> </section> <section id="CD011439-sec-0099"> <h5 class="title">2. Use of spirometry or peak flow as an adjunctive monitoring tool for adjustment of medications (versus non‐use of spirometry or peak flow) </h5> <p>Five studies utilised spirometry when adjusting medications in the control group (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>); however, spirometry was not the sole measurement for adjusting the medications, therefore this subgroup analysis could not be done. As per <a href="#CD011439-tbl-0002">Table 1</a>, all five studies used asthma guidelines which included participant‐reported symptoms, SABA use and spirometry. </p> </section> <section id="CD011439-sec-0100"> <h5 class="title">3. Baseline inhaled corticosteroid dose at commencement of intervention (low‐medium (&lt; 800 μg/day of budesonide equivalent) versus high dose (800 μg/day or more of budesonide equivalent)) </h5> <p>In six studies, the median ICS dose at baseline was less than 800 μg/day of budesonide equivalent (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). However, none of the studies analysed their data based on baseline ICS dose, hence this subgroup analysis could not be done. </p> <p>One study did not provide the daily ICS dosage in micrograms per day so could not be included in this subgroup analysis (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). </p> </section> <section id="CD011439-sec-0101"> <h5 class="title">4. Fractional exhaled nitric oxide cut‐offs for adjustment of medications (20 ppb or less versus more than 20 ppb) </h5> <p>Three studies adjusted medications when the FeNO levels were 20 ppb or less as described in <a href="#CD011439-tbl-0002">Table 1</a> (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). When considering this in the subgroup analysis, the results were similar to the main analyses. </p> <p>By removing <a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; and <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a> (in <a href="./references#CD011439-fig-0004" title="">Analysis 1.1</a>) who adjusted medications when FeNO was greater than 20 ppb from the first outcome (number of participants who had one or more exacerbations), the difference between groups remained statistically different (P = 0.0007; OR 0.25, 95% CI 0.11 to 0.56; I<sup>2</sup> = 0%). Likewise, for the second outcome of exacerbation rates, by removing <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a> and <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>, the difference between groups favoured the FeNO group (MD ‐0.63, 95% CI ‐0.98 to ‐0.27; I<sup>2</sup> = 65%). </p> </section> <section id="CD011439-sec-0102"> <h5 class="title">5. Fractional exhaled nitric oxide cut‐offs, based on presence of atopy</h5> <p>Only one study considered atopy in their algorithm for FeNO levels (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). Removing this study from the primary outcomes of exacerbations, the meta‐analyses results still significantly favoured the FeNO group. For the first outcome, the number of participants who had more than one exacerbation over the study period, the difference between groups remained statistically different (OR 0.65, 95% CI 0.51 to 0.85; I<sup>2</sup> = 9%). Likewise, for the exacerbation rates, removing <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a> from the FeNO group also resulted in a statistically difference between groups (MD ‐0.27, 95% CI ‐0.49 to ‐0.06; I<sup>2</sup> = 77%). </p> </section> </section> <section id="CD011439-sec-0103"> <h4 class="title">Sensitivity analyses</h4> <section id="CD011439-sec-0104"> <h5 class="title">1. Excluding studies with a high risk of bias based on the 'Risk of bias' assessment</h5> <p>There were three included studies which had no blinding (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). However, when the data from these studies was removed it did not alter the results of the primary outcome (exacerbations) found in the main analyses. Summary data for the number of participants who had one or more exacerbations over the study period (OR 0.67, 95% CI 0.50 to 0.89; 887 participants; 5 studies) and exacerbation rate (MD ‐0.2, 95% CI ‐0.41 to 0.0; 672 participants; 3 studies) still favoured the FeNO group. </p> </section> <section id="CD011439-sec-0105"> <h5 class="title">2. Variation in the inclusion criteria</h5> <p>Three studies reported that not all included children were receiving ICS at recruitment (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>). Removing <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a> and <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a> from the analyses resulted in similar results (i.e. outcomes favoured the FeNO group); the number of participants who had one or more exacerbations (OR 0.64, 95% CI 0.49 to 0.84; 1125 participants; 6 studies). Likewise, the group differences for exacerbation rate remained significantly different between groups favouring the FeNO group (MD ‐0.23, 95% CI ‐0.43 to ‐0.02; 609 participants; 2 studies). </p> </section> <section id="CD011439-sec-0106"> <h5 class="title">3. Differences in the medications used in the intervention and comparison group</h5> <p>There were no studies that adjusted medications only for one arm, therefore this planned sensitivity analysis was not undertaken. </p> </section> <section id="CD011439-sec-0107"> <h5 class="title">4. Analysis using random‐effects model</h5> <p>Using a random‐effects model did not change the significant group differences between the groups (i.e. favoured the FeNO group), in the number of participants who had one or more exacerbations over the study period (OR 0.58, 95% CI 0.42 to 0.81; 1279 participants; 8 studies). </p> <p>Due to the high levels of heterogeneity (I<sup>2</sup> = 67%), we used a random‐effects model to analyse number of exacerbations per 52 weeks, which resulted in a non‐statistically significant estimate favouring the FeNO group (MD ‐0.37, 95% CI ‐0.80 to 0.06; 736 participants; 4 studies). There was a significant difference between groups when a fixed‐effect model was applied (MD ‐0.30, 95% CI ‐0.49 to ‐0.10; 736 participants; 4 studies), but this latter model is considered less appropriate in the context of high levels of heterogeneity. </p> </section> <section id="CD011439-sec-0108"> <h5 class="title">5. Analysis by 'strategy received'</h5> <p>One study used a hierarchy management protocol that was based solely on the use of steroids for each step (i.e. without consideration for using montelukast or LABA, or both, at any point) (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>). Removing this study from the analyses did not alter the significant group differences found in the main analyses. The number of participants who had one or more exacerbations over the study period favoured the FeNO arm (OR 0.62, 95% CI 0.48 to 0.8; 1190 participants; 7 studies). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011439-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011439-sec-0109">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011439-sec-0177">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011439-sec-0109"></div> <section id="CD011439-sec-0110"> <h3 class="title" id="CD011439-sec-0110">Summary of main results</h3> <p>The nine RCTs included in this review involved 1426 children (1329 completed). The studies varied in many aspects including the FeNO levels used, the algorithms, study duration and the strategy used for the control arm. </p> <p>All studies reported our review's primary outcome (exacerbation). However, the studies defined exacerbation in various ways. Data from eight studies were combined for the meta‐analysis of the outcome, number of participants having one or more asthma exacerbation. Significantly fewer children in the FeNO group had exacerbations compared to the control group (OR 0.58, 95% CI 0.45 to 0.75). The NNTB over 52 weeks was 9 (95% CI 6 to 15). There was no difference between the groups when comparing the exacerbation rates (MD ‐0.37, 95% CI ‐0.8 to 0.06). When combining seven studies, we found that fewer children in the FeNO group required rescue courses of oral corticosteroids compared to controls (OR 0.63, 95% CI 0.48 to 0.83). However, there was no difference between the groups for severe exacerbations requiring hospitalisation (OR 0.75, 95% CI 0.41 to 1.4). There were 20 hospitalisations in the FeNO group versus 26 in the control group. </p> <p>In the subgroup analyses, the main analyses for the primary outcome of exacerbations continued to favour the FeNO group when restricting the analysis to the studies that utilised guidelines for the control group (number of participants who had one or more exacerbation: OR 0.67, 95% CI 0.51 to 0.90; exacerbation rate: MD ‐0.27, 95% CI‐0.49 to ‐0.06). There was no statistical difference between the subgroups in these analyses. </p> <p>In the sensitivity analyses, the only changes seen in the primary outcome analyses was when we applied the fixed‐effect analysis to the outcome exacerbation rates per 52 weeks. As per our protocol, we chose to perform our primary analysis of this outcome with a random‐effects model, which is more appropriate in the context of the substantial heterogeneity detected (I<sup>2</sup> = 67%). Unlike the random‐effects model, the fixed‐effect model resulted in a statistically significant estimate favouring the FeNO group (MD ‐0.30, 95% CI ‐0.49 to ‐0.10; 736 participants; 4 studies). However, the number of participants who had one or more exacerbation over the study period (analysed primarily with a fixed‐effect model) remained favourable towards the FeNO group when a sensitivity analysis was performed with a random‐effects model (OR 0.58, 95% CI 0.42 to 0.81). </p> <p>In contrast to the data relating to exacerbations, there was no significant difference between groups for any of the secondary outcomes (FEV<sub>1</sub>, FeNO levels, symptom scores or final ICS dose). </p> </section> <section id="CD011439-sec-0111"> <h3 class="title" id="CD011439-sec-0111">Overall completeness and applicability of evidence</h3> <p>This review included nine studies but not all studies could be included in every outcome for the meta‐analyses. The meta‐analyses consisted of data from two to eight studies. The number of children for the various outcomes ranged from 317 (outcome: ICS dose at final visit) to 1297 (outcome: Number of participants who had one or more exacerbations over the study period). Therefore, the completeness of the review was limited by the available data, although we contacted the authors of the included studies for additional data. </p> <p>Two of the primary outcomes ('Number of participants who had one or more exacerbations over the study period' and 'Severe exacerbations requiring oral corticosteroids') favoured the FeNO arm, however there was no significant group differences for 'Exacerbation rate', 'Severe exacerbations requiring hospitalisation' or for any secondary outcomes (symptom scores, FeNO at end of study, FEV<sub>1</sub> at end of study or ICS doses). There were no changes in the primary outcomes when subgroup analysis was undertaken with FeNO group being favoured in three out of four of the primary analyses. </p> <p>All nine studies were hospital‐based and undertaken since the early 2000's in affluent countries; three in the Netherlands (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>), one in Austria (<a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>), one in Belgium (<a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>), one in Australia (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), one in the UK (<a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>), one in the USA (<a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>), and one in Italy (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). There is a gap of evidence from the low‐income countries, therefore limiting this review's findings in resource‐poor settings. Likewise, none of the included studies were from a primary care setting, therefore restricting interpretation of these findings to hospital settings only (as children looked after in primary care are likely to have less severe asthma). </p> <p>Guidelines on the interpretation of FeNO levels suggest using a cut‐off of less than 20 ppb as normal and more than 35 ppb as reflective of the presence of inflammation in children (<a href="./references#CD011439-bbs2-0037" title="DweikRA , BoggsPB , ErzurumSC , IrvinCG , LeighMW , LundbergJO , et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American Journal of Respiratory and Critical Care Medicine2011;184(5):602‐15. [DOI: 10.1164/rccm.9120‐11ST] ">Dweik 2011</a>). However, it remains unknown how other significant influences of FeNO should be considered. These influences include ethnicity (<a href="./references#CD011439-bbs2-0031" title="American Thoracic Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of FeNO. American Journal of Critical Care and Respiratory Medicine2005;171(8):912‐30. [DOI: 10.1164/rccm.200406‐710ST] ">ATS 2005</a>) and atopy (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>). Further, the FeNO cut‐off values used to adjust the medications varied among the studies although it could be argued that the cut‐off used should be individualised with each child having their own baseline FeNO value. None of the studies used this approach. Thus, it remains unknown how best to use FeNO values. </p> <p>Also, as FeNO levels reflect airway eosinophilia in steroid‐naive people, the results of the review are unlikely to apply to those children with non‐eosinophilic asthma. </p> <p>In our review, there was a discordance between the beneficial effect of using FeNO to guide asthma therapy for exacerbations compared to other clinically important outcomes such as QoL, asthma control and lung function. One possible reason relates to a type‐1 error (insufficient sample size). However, 724 participants used the ACQ and 380 participants used the PACQLQ. Thus, it is unlikely that there was a type‐1 error present. </p> <p>Lastly, none of the studies included in this review undertook a cost analyses and its absence limits the applicability in 'real‐life' clinical practice. </p> </section> <section id="CD011439-sec-0112"> <h3 class="title" id="CD011439-sec-0112">Quality of the evidence</h3> <p>The 'Summary of findings' table summarises the evidence for the three main outcomes relating to exacerbations and ICS dose. Overall the quality of evidence was very low to moderate using the GRADE system. As two studies were not blinded (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>) and another (<a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>) was single blinded this reduced our confidence in these studies as they introduced bias. Removing these studies for the sensitivity analysis, still showed a reduction in the number of exacerbations in the FeNO group. However, we downgraded the evidence using GRADE to moderate as displayed in <a href="./full#CD011439-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We downgraded the outcome of exacerbation rate to very low due to the statistical heterogeneity (I<sup>2</sup> = 67%, P = 0.03), imprecision and risk of bias. The fact that a random‐effects model showed no difference between the groups, whereas a fixed‐effect model did show a difference, demonstrates the imprecision and potential skew of the data. The study that likely contributed to the statistical heterogeneity was that of <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a> who stated that their data for exacerbation rates was skewed when they provided further data to us. Consequently, they reported their published data as medians and interquartile ranges. </p> </section> <section id="CD011439-sec-0113"> <h3 class="title" id="CD011439-sec-0113">Potential biases in the review process</h3> <p>We are unaware of any biases in the review process. We used a comprehensive search strategy and adhered to the protocol. Two review authors (HP, KK) independently assessed the risk of bias. We contacted the corresponding authors of all the studies for raw data to include in the meta‐analysis. One review author and the review editor (Christopher Cates) independently checked data extraction, risk of bias assessment and downgrading decisions for the 'Summary of findings' tables to minimise the risk of bias in the review process. </p> <p>As two of the review authors (HP, AC) conducted one of the studies included in this review (<a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>), a separate review author (KK) made final decisions on this paper's risk of bias. </p> </section> <section id="CD011439-sec-0114"> <h3 class="title" id="CD011439-sec-0114">Agreements and disagreements with other studies or reviews</h3> <p>This review updated a previous Cochrane Review (<a href="./references#CD011439-bbs2-0051" title="PetskyHL , CatesCJ , LiA , KynastonJA , TurnerC , ChangAB . Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006340.pub3] ">Petsky 2009</a>), which included studies involving children and adults. The decision was to separate the review based on population ages and the increased clinical trials on the subject. The original review included two adult studies and four paediatric studies involving 1010 participants (<a href="./references#CD011439-bbs2-0051" title="PetskyHL , CatesCJ , LiA , KynastonJA , TurnerC , ChangAB . Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006340.pub3] ">Petsky 2009</a>). This paediatric review includes nine studies with 1329 children completing. A separate systematic review on adults includes seven studies with 1546 participants completing (<a href="./references#CD011439-bbs2-0048" title="PetskyHL , KewKM , TurnerC , ChangAB . Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database of Systematic Reviews2016, Issue 9. [DOI: 10.1002/14651858.CD011440.pub2] ">Petsky 2016</a>). The review in adults found similar results to this paediatric review. </p> <p>Results from the original review (<a href="./references#CD011439-bbs2-0051" title="PetskyHL , CatesCJ , LiA , KynastonJA , TurnerC , ChangAB . Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006340.pub3] ">Petsky 2009</a>) were different to those of this current review. The old review found no significant difference between the groups for the primary outcome of exacerbations. The four paediatric papers included in the original review reported that the FeNO group experienced fewer exacerbations in comparison to the control group, but the difference was not significant (P = 0.06) when combining three studies in a meta‐analysis (OR 0.75, 95% CI 0.55 to 1.01) (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>). However, combining the data from eight studies in this review showed that the number of participants experiencing an exacerbation was significantly lower (P = 0.0002) in the FeNO group compared to the control group (OR 0.62, 95% CI 0.49 to 0.80) (<a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a>; <a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a>; <a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a>; <a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a>; <a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). There was no heterogeneity between the studies (I<sup>2</sup> = 21%). </p> <p><a href="./references#CD011439-bbs2-0044" title="LuM , WuB , CheD , QiaoR , GuH . FeNO and asthma treatment in children. Medicine2015;94(4):e347. [DOI: 10.1097/MD.0000000000000347] ">Lu 2015</a> completed a meta‐analysis comparing the use of FeNO versus guideline‐based management for children with asthma. They included six studies with 506 participants. Their results were similar to this Cochrane Review. Lu and coworkers described that significantly fewer participants in the FeNO group had exacerbations compared to the control group (more than one exacerbation: OR 0.69, 95% CI 0.53 to 0.90; P = 0.005). As with this Cochrane Review, <a href="./references#CD011439-bbs2-0044" title="LuM , WuB , CheD , QiaoR , GuH . FeNO and asthma treatment in children. Medicine2015;94(4):e347. [DOI: 10.1097/MD.0000000000000347] ">Lu 2015</a> described no difference between groups for the outcomes of FeNO levels, FEV<sub>1</sub> or ICS dose. </p> <p>Gomersal and colleagues conducted a systematic review but did not undertake a meta‐analysis comparing FeNO‐guided management with any other monitoring strategy for children with asthma (<a href="./references#CD011439-bbs2-0039" title="GomersalT , HarnanS , EssatM , TappendenP , WongR , LawsonR , et al. A systematic review of fractional exhaled nitric oxide in the routine management of childhood asthma. Pediatric Pulmonology2016;51(3):316‐28. [DOI: 10.1002/ppul.23371] ">Gomersal 2016</a>). Their review included seven studies and the authors stated that there was a "trend towards reduced exacerbation and increased medications use" in the FeNO group. Furthermore, they identified issues with heterogeneity between the algorithms and included cohorts. They concluded that the benefits of utilising FeNO monitoring in children with asthma remains ambiguous. </p> <p>There are no guidelines currently that recommend the use of FeNO routinely in monitoring asthma. However, guidelines from the National Institute for Health and Care Excellence are currently focusing on the impact and feasibility of implementing FeNO in a diagnosis algorithm (<a href="./references#CD011439-bbs2-0047" title="National Institute for Health and Care Excellence. Asthma: diagnosing and monitoring of asthma in adults, children and young people. www.nice.org.uk/guidance/indevelopment/gid‐cgwave0640/documents (accessed 18 January 2016). ">NICE interim findings 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011439-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Prisma flow diagram." data-id="CD011439-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Prisma flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011439-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="In the control group, 40 children out of 100 had exacerbations over one year, compared to 29 (95% confidence interval (CI) 25 to 35) out of 100 for the active treatment group. Number needed to treat for one additional beneficial outcome = 10 (95% CI 7 to 20)." data-id="CD011439-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>In the control group, 40 children out of 100 had exacerbations over one year, compared to 29 (95% confidence interval (CI) 25 to 35) out of 100 for the active treatment group. Number needed to treat for one additional beneficial outcome = 10 (95% CI 7 to 20). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 1 Number of participants who had ≥ 1 exacerbations over study period." data-id="CD011439-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 1 Number of participants who had ≥ 1 exacerbations over study period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 2 Number of asthma exacerbations per 52 weeks (exacerbation rates)." data-id="CD011439-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 2 Number of asthma exacerbations per 52 weeks (exacerbation rates). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 3 Number of participants with severe exacerbations requiring hospitalisation." data-id="CD011439-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 3 Number of participants with severe exacerbations requiring hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 4 Number of participants with severe exacerbations requiring rescue oral corticosteroids." data-id="CD011439-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 4 Number of participants with severe exacerbations requiring rescue oral corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 5 FEV1 %predicted at final visit." data-id="CD011439-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 5 FEV<sub>1</sub> %predicted at final visit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 6 FeNO geometric mean level at final visit." data-id="CD011439-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 6 FeNO geometric mean level at final visit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 7 Symptom score as per Asthma Control Test." data-id="CD011439-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 7 Symptom score as per Asthma Control Test. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 8 Symptom score as per quality of life." data-id="CD011439-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 8 Symptom score as per quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 9 Inhaled corticosteroid dose at final visit (budesonide equivalent)." data-id="CD011439-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 9 Inhaled corticosteroid dose at final visit (budesonide equivalent). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 10 Number of participants who had ≥ 1 exacerbations over study period (subgrouped by method used in control group).." data-id="CD011439-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 10 Number of participants who had ≥ 1 exacerbations over study period (subgrouped by method used in control group).. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011439-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/urn:x-wiley:14651858:media:CD011439:CD011439-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_t/tCD011439-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 11 Number of exacerbations per 52 weeks (exacerbation rates) (subgrouped by method used in control group)." data-id="CD011439-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms, Outcome 11 Number of exacerbations per 52 weeks (exacerbation rates) (subgrouped by method used in control group). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/media/CDSR/CD011439/image_n/nCD011439-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011439-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tailoring asthma treatment using fractional exhaled nitric oxide versus clinical symptoms</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with asthma<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> asthma treatment tailored on FeNO<br/> <b>Comparison:</b> asthma treatment tailored on clinical symptoms </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clinical symptoms</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with asthma treatment tailored on FeNO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants who had ≥ 1 exacerbations over study period</p> <p>(48.5 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 100<br/> (25 to 35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.62<br/> (0.49 to 0.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1279<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of asthma exacerbations per 52 weeks (exacerbation rate)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of asthma exacerbations per 52 weeks (exacerbation rate) was 1.66</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of asthma exacerbations per 52 weeks (exacerbation rate) in the intervention group was 0.37 lower (0.8 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.37 (‐0.8 to 0.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>736<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICS dose at final visit (budesonide equivalent)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ICS dose at final visit (budesonide equivalent) was <b>483 μg/day</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ICS dose at final visit (budesonide equivalent) in the intervention group was 63.95 μg/day higher (51.89 lower to 179.79 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FeNO:</b> fractional exhaled nitric oxide; <b>ICS:</b> inhaled corticosteroid; <b>MD:</b> mean difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Three studies carrying 23.7% of the analysis weight were at high risk of performance bias and detection bias due to the lack of blinding (downgraded one level risk of bias) (<a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a>; <a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>; <a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> <p><sup>2</sup>One study carrying 11% of the analysis weight was open labelled which may have introduced detection bias (<a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a>). A random‐effects sensitivity analysis substantially changed the result to MD ‐0.37 (95% CI ‐0.8 to 0.06). There was also statistical heterogeneity in the analysis (I<sup>2</sup> = 67%, P = 0.03) (downgrade three levels for risk of bias, imprecision and heterogeneity). </p> <p><sup>3</sup>One study carrying 47% of the analysis weight was single blinded and participants were aware of their allocation group (downgraded one level for performance bias) (<a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tailoring asthma treatment using fractional exhaled nitric oxide versus clinical symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011439-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies definitions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exacerbation definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FeNO strategy (FeNO levels in ppb)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom strategy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0001" title="deJongsteJ , CarraroS , HopW , the CHARISM Study Group, BaraldiE . Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine2008;179(2):93‐7. [DOI: 10.1164/rccm.200807‐1010OC] ">de Jongste 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided</p> <p>(OCS courses and hospitalisation data included</p> <p>in exacerbation results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In children aged 6 to 10 years:</p> <p>&lt; 20 and ≤ 60 symptom score = step down/discontinue</p> <p>&gt; 20 and ≤ 60 symptom score = increase</p> <p>&lt; 20 and &gt; 60 symptom score = no change</p> <p>&gt; 20 and &gt; 60 symptom score = step up</p> <p>In children aged &gt; 10 years:</p> <p>&lt; 25 and ≤ 60 symptom score = step down/discontinue</p> <p>&gt; 25 and ≤ 60 symptom score = increase</p> <p>&lt; 25 and &gt; 60 symptom score = no change</p> <p>&gt; 25 and &gt; 60 symptom score = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Below range (&lt; 10) = step down/discontinue</p> <p>In range (10 to 60) = no change</p> <p>Above range (&gt; 60) = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0002" title="FritschM , UxaS , HorakF , PutschoeglB , DehlinkE , SzepfalusiZ , et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6‐months study. Pediatric Pulmonology2006;41(9):855‐62. [DOI: 10.1002/ppul.20455] ">Fritsch 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 parameters:</p> <p>OCS because of asthma symptoms,</p> <p>non‐scheduled visit because of asthma</p> <p>symptoms, &gt; symptom score to 2,</p> <p>&lt; FEV<sub>1</sub> (in litres) &gt; 10% compared to </p> <p>previous visit, or a combination of these</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 20 and FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = step down</p> <p>≤ 20 and FEV<sub>1</sub> &lt; 80% or symptoms score &gt; 1 or SABA </p> <p>use ≥ 6 = step up</p> <p>Participant on SABA on demand only:</p> <p>&gt; 20 and FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = step up</p> <p>Participant on ICS:</p> <p>&gt; 20 and FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = same step</p> <p>&gt; 20 and FEV<sub>1</sub> &lt; 80% or symptoms score &gt; 1 or SABA </p> <p>use ≥ 6 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austrian asthma guidelines:</p> <p>FEV<sub>1</sub> ≥ 80%, symptom score 0 or 1 and SABA </p> <p>use &lt; 6 = step down</p> <p>FEV<sub>1</sub> &lt; 80% or symptoms score &gt; 1 or SABA </p> <p>use ≥ 6 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0003" title='PeirsmanE , CarvelliT , HageP , HanssensL , PattynL , RaesM , et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatric Pulmonology2014;49(7):624‐31. [DOI: 10.1002.ppul.22873] Peirsman , E . Response to the Editor: "Fractional exhaled nitric oxide‐guided algorithm for children with allergic asthma". Pediatric Pulmonology2015;50(9):934‐5. [DOI: 10.1002/ppul.23137] QunUi , Lee . Fractional exhaled nitric oxide‐guided algorithm for children with asthma. Pediatric Pulmonology2015;50(9):932‐3. [DOI: 10.1002/ppul.23115] '>Peirsman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As per GINA guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 20 and controlled = step down</p> <p>≤ 20 and partially controlled consider LTRA</p> <p>&gt; 20 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GINA guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0004" title="PetskyH , LiA , AuC , KynastonJ , TurnerC , ChangA . Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatric Pulmonology2015;50(6):535‐43. [DOI: 10.1002/ppul.23064] ">Petsky 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory events requiring OCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elevated FeNO = step up</p> <p>Low FeNO for 2 visits = step down</p> <p>Elevated FeNO defined as:</p> <p>≥ 10 with no positive SPT</p> <p>≥ 12 with 1 positive SPT</p> <p>≥ 20 with ≥ 2 positive SPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma symptom diary card</p> <p>Score &lt; 10 in previous week = step down</p> <p>Score increased ≥ 15% since previous week</p> <p>= step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0005" title="PijnenburgM , BakkerE , HopW , deJongsteJ . Titrating steroids on exhaled nitric oxide in children with asthma. American Journal of Respiratory and Critical Care Medicine2005;172(7):831‐6. [DOI: 10.1164/rccm.200503‐4580C] ">Pijnenburg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided</p> <p>(OCS courses included in results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 30 and symptom score ≤ 14 = step down</p> <p>≤ 30 and symptom score &gt; 14 = no change</p> <p>&gt; 30, regardless of symptoms = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≤ 14 second time = step down</p> <p>Symptom score ≤ 14 first time = no change</p> <p>Symptom score &gt; 14 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0006" title="PikeK , SelbyA , PriceS , WarnerJ , ConnettG , LeggJ , et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid does in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal2013;7(2):204‐13. [DOI: 10.1111/j.1752‐699X.2012.00306.x] ">Pike 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 48 hours &gt; asthma symptoms or therapy or &lt; PEF (≥25%).</p> <p>Mild: increase SABA only</p> <p>Moderate: requiring systemic corticosteroids</p> <p>Severe: requiring hospitalisations ≥ 8 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 15 and well controlled = step down</p> <p>&lt; 25 and poorly controlled = LABA maximised</p> <p>≥ 25 or FeNO doubled from baseline = step up</p> <p>If FeNO remained raised after 2 x steps (SIGN/BTS</p> <p>steps) ICS not increased again unless participant</p> <p>poorly controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SIGN/BTS guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0007" title="GruchallaRS , SampsonHA , MatsuiE , DavidG , GergenPJ , CalatroniA , et al. Asthma morbidity among inner‐city adolescents receiving guidelines‐based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology2009;124(2):213‐21. [DOI: 10.1016/j.jaci2009.05.036] PedersenS , O'ByrnePM . Exhaled nitric oxide in guideline‐based asthma management. Lancet2008;372(9643):1015‐7. SzeflerS , MitchellH , SorknessC , GergenP , O'ConnorG , MorganW , et al. Management of asthma based on exhaled nitric oxide in addition to guideline‐based treatment for inner‐city adolescents and young adults: a randomised controlled trial. Lancet2008;372(9643):1065‐72. [DOI: 10.1016/S0140‐6736(08)61448‐8] TaylorDR , BushA . Clinical use of exhaled nitric oxide measurements. Lancet2009;373(9661):382. ">Szefler 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admissions to hospital, unscheduled visits and</p> <p>prednisone use for asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NHLBI guidelines and FeNO</p> <p>≤ 20 and Level 1 = no change</p> <p>20.1 to 30 and Level 2 = step up</p> <p>30.1 to 40 and Level 3 = 2 steps</p> <p>&gt; 40 and Level 4 = 3 steps or 2 steps and OCS course</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NHLBI guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0008" title="VeriniM , ConsilvioN , DiPilloS , CingolaniA , SpagnuoloC , RapinoD , et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. Journal of Allergy2010;2010:pii: 691425. [DOI: 10.1155/2010/691425] ">Verini 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>According to ATS/ERS criteria and requiring<br/> SABA. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 month visit only:</p> <p>&lt; 12 = step down or no change</p> <p>&gt; 12 = step up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As per GINA:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011439-bbs2-0009" title="BeerthuizenT , Voorend‐van BergenS , van denHoutW , Vaessen‐VerberneA , BrackelH , LandstraA , et al. Cost‐effectiveness of FeNO‐based and web‐based monitoring in paediatric asthma management: a randomised controlled trial. Thorax2016;71(7):607‐13. [DOI: 10.1136/thoraxjnl‐2015‐207593] Voorend‐van BergenS , Vaessen‐VerberneAA , BrackelHJ , LandstraAM , van denBergNJ , HopWC , et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax2015;70(6):543‐50. [DOI: 10.1136/thoraxjnl‐2014‐206161] Voorend‐van BergenS , Vaessen‐VerberneAA , LandstraAM , BrackelHJ , van denBergNJ , MerkusPJ , et al. Fractional exhaled nitric oxide monitoring does not improve asthma management in children with concordant and discordant asthma phenotypes. American Journal of Respiratory and Critical Care Medicine2015;192(8):1016‐8. [DOI: 10.1164/rccm.201506‐1103LE] ">Voorend‐van Bergen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided</p> <p>(OCS courses and hospitalisation data included</p> <p>in exacerbation results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If ACT ≥ 20 and:</p> <p>FeNO &lt; 25 = step down</p> <p>FeNO ≥ 25 to &lt; 50 = no change</p> <p>FeNO ≥ 50 = step up</p> <p>If ACT &lt; 20 and:</p> <p>FeNO ≥ 25 = step up</p> <p>FeNO &lt; 25 = no change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACT results:</p> <p>&lt; 20 = step up</p> <p>≥ 20 = no change or step</p> <p>down</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ACT: Asthma Control Test; ATS: American Thoracic Society; BTS: British Thoracic Society; ERS: European Respiratory Society; FeNO: fractional exhaled nitric oxide; FEV<sub>1</sub>: forced expiratory volume in first second; GINA: Global initiative for asthma; ICS: inhaled corticosteroids; LTRA: leukotriene receptor antagonist; NHLBI: National Heart, Lung, and Blood Institute; OCS: oral corticosteroids; ppb: parts per billion; SABA: short‐acting beta<sub>2</sub> agonist; SIGN: Scottish Intercollegiate Guidelines Network; SPT: skin prick test. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies definitions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/full#CD011439-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011439-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants who had ≥ 1 exacerbations over study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.49, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of asthma exacerbations per 52 weeks (exacerbation rates) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.80, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants with severe exacerbations requiring hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.41, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with severe exacerbations requiring rescue oral corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.48, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 FEV<sub>1</sub> %predicted at final visit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.07, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FeNO geometric mean level at final visit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Symptom score as per Asthma Control Test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.18, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Symptom score as per quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.08, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Inhaled corticosteroid dose at final visit (budesonide equivalent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>63.95 [‐51.89, 179.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of participants who had ≥ 1 exacerbations over study period (subgrouped by method used in control group). <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Guideline driven</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.51, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Other control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.34, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number of exacerbations per 52 weeks (exacerbation rates) (subgrouped by method used in control group) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Guideline driven</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.49, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Other control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.84, 0.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011439.pub2/references#CD011439-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011439.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011439-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011439-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011439-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011439-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011439-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011439-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011439-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011439\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011439\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011439\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011439\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011439\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011439.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011439.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011439.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011439.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011439.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713770015"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011439.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713770019"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011439.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d5e5ee8ab936e',t:'MTc0MDcxMzc3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 